Pharmacyte Biotech Stock Price History
| PMCB Stock | USD 2.20 0.08 3.77% |
Below is the normalized historical share price chart for PharmaCyte Biotech extending back to September 11, 2003. This chart has been adjusted for all splits and dividends and is plotted against all major global economic recessions. As of today, the current price of PharmaCyte Biotech stands at 2.20, as last reported on the 19th of April, with the highest price reaching 2.31 and the lowest price hitting 2.07 during the day.
If you're considering investing in PharmaCyte Stock, it is important to understand the factors that can impact its price. We consider PharmaCyte Biotech risky. PharmaCyte Biotech maintains Sharpe Ratio (i.e., Efficiency) of 0.0188, which implies the firm had a 0.0188% return per unit of risk over the last 3 months. We have found twenty-nine technical indicators for PharmaCyte Biotech, which you can use to evaluate the volatility of the company. Please check PharmaCyte Biotech's Semi Deviation of 2.62, coefficient of variation of 4219.13, and Risk Adjusted Performance of 0.0225 to confirm if the risk estimate we provide is consistent with the expected return of 0.0526%.
At present, PharmaCyte Biotech's Total Stockholder Equity is projected to increase significantly based on the last few years of reporting. The current year's Other Stockholder Equity is expected to grow to about 227.8 M, whereas Common Stock Total Equity is forecasted to decline to 173.71. . At present, PharmaCyte Biotech's Price To Sales Ratio is projected to increase significantly based on the last few years of reporting. The current year's Price Book Value Ratio is expected to grow to 0.74, whereas Price Earnings Ratio is forecasted to decline to (15.92). PharmaCyte Stock price history is provided at the adjusted basis, taking into account all of the recent filings.
IPO Date 17th of September 2010 | 200 Day MA 2.297 | 50 Day MA 2.1884 | Beta (0.16) |
PharmaCyte |
Sharpe Ratio = 0.0188
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | PMCB | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 2.8 actual daily | 24 76% of assets are more volatile |
Expected Return
| 0.05 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| 0.02 actual daily | 1 99% of assets perform better |
Based on monthly moving average PharmaCyte Biotech is performing at about 1% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of PharmaCyte Biotech by adding it to a well-diversified portfolio.
Price Book 0.6008 | Book Value 3.682 | Enterprise Value -20.5 M | Enterprise Value Ebitda 6.0328 | Shares Float 8.1 M |
PharmaCyte Biotech Stock Price History Chart
There are several ways to analyze PharmaCyte Stock price data. The simplest method is using a basic PharmaCyte candlestick price chart, which shows PharmaCyte Biotech price history and the buying and selling dynamics of a specified period. Many traders also use subjective judgment to their trading calls, avoiding the need to trade based on technical analysis.
| Highest Price | April 4, 2024 | 2.52 |
| Lowest Price | March 15, 2024 | 1.95 |
PharmaCyte Biotech April 19, 2024 Stock Price Synopsis
Various analyses of PharmaCyte Biotech's daily price changes, such as its Balance Of Power or Price Action, are crucial when deciding whether to buy, hold, or sell PharmaCyte Stock. It can be used to describe the percentage change in the price of PharmaCyte Biotech from one trading day to the next and could be a valuable metric for traders and investors to gauge the volatility and momentum of PharmaCyte Stock.| PharmaCyte Biotech Price Daily Balance Of Power | 0.33 | |
| PharmaCyte Biotech Price Rate Of Daily Change | 1.04 | |
| PharmaCyte Biotech Price Action Indicator | 0.05 |
PharmaCyte Biotech April 19, 2024 Stock Price Analysis
PharmaCyte Stock Price History Data
The price series of PharmaCyte Biotech for the period between Sat, Jan 20, 2024 and Fri, Apr 19, 2024 has a statistical range of 0.57 with a coefficient of variation of 6.83. The price distribution for the period has arithmetic mean of 2.2. The median price for the last 90 days is 2.18. The company completed stock split (1:1550) on 12th of July 2021.| Open | High | Low | Close | Volume | ||
04/19/2024 | 2.07 | 2.31 | 2.07 | 2.20 | ||
| 04/18/2024 | 2.07 | 2.31 | 2.07 | 2.20 | 5,886 | |
| 04/17/2024 | 2.12 | 2.31 | 2.12 | 2.12 | 8,821 | |
| 04/16/2024 | 2.11 | 2.16 | 2.07 | 2.15 | 12,303 | |
| 04/15/2024 | 2.18 | 2.39 | 2.11 | 2.11 | 26,471 | |
| 04/12/2024 | 2.27 | 2.46 | 2.23 | 2.23 | 38,104 | |
| 04/11/2024 | 2.23 | 2.40 | 2.23 | 2.30 | 33,629 | |
| 04/10/2024 | 2.23 | 2.29 | 2.23 | 2.26 | 8,938 | |
| 04/09/2024 | 2.36 | 2.38 | 2.30 | 2.30 | 19,663 | |
| 04/08/2024 | 2.40 | 2.45 | 2.31 | 2.39 | 15,781 | |
| 04/05/2024 | 2.46 | 2.50 | 2.42 | 2.42 | 12,120 | |
| 04/04/2024 | 2.55 | 2.55 | 2.46 | 2.52 | 13,059 | |
| 04/03/2024 | 2.44 | 2.54 | 2.44 | 2.51 | 29,095 | |
| 04/02/2024 | 2.42 | 2.50 | 2.42 | 2.48 | 51,066 | |
| 04/01/2024 | 2.36 | 2.44 | 2.36 | 2.44 | 20,010 | |
| 03/28/2024 | 2.42 | 2.50 | 2.29 | 2.37 | 34,542 | |
| 03/27/2024 | 2.34 | 2.58 | 2.34 | 2.44 | 14,826 | |
| 03/26/2024 | 2.56 | 2.56 | 2.34 | 2.44 | 345,489 | |
| 03/25/2024 | 2.45 | 2.54 | 2.45 | 2.48 | 56,028 | |
| 03/22/2024 | 2.45 | 2.45 | 2.34 | 2.44 | 39,057 | |
| 03/21/2024 | 2.35 | 2.50 | 2.34 | 2.41 | 52,991 | |
| 03/20/2024 | 2.08 | 2.40 | 2.07 | 2.38 | 114,086 | |
| 03/19/2024 | 1.96 | 2.20 | 1.96 | 2.14 | 120,832 | |
| 03/18/2024 | 1.94 | 2.10 | 1.94 | 2.01 | 29,992 | |
| 03/15/2024 | 1.98 | 2.09 | 1.95 | 1.95 | 43,589 | |
| 03/14/2024 | 1.98 | 2.04 | 1.97 | 2.04 | 28,844 | |
| 03/13/2024 | 1.97 | 2.02 | 1.94 | 1.98 | 14,365 | |
| 03/12/2024 | 1.98 | 2.05 | 1.97 | 1.97 | 10,877 | |
| 03/11/2024 | 2.03 | 2.06 | 2.00 | 2.01 | 10,929 | |
| 03/08/2024 | 2.05 | 2.09 | 2.05 | 2.06 | 6,861 | |
| 03/07/2024 | 2.02 | 2.06 | 2.02 | 2.05 | 10,925 | |
| 03/06/2024 | 2.01 | 2.08 | 2.01 | 2.03 | 19,368 | |
| 03/05/2024 | 2.03 | 2.09 | 2.02 | 2.03 | 7,142 | |
| 03/04/2024 | 2.08 | 2.10 | 2.05 | 2.05 | 19,170 | |
| 03/01/2024 | 2.08 | 2.13 | 2.07 | 2.08 | 5,703 | |
| 02/29/2024 | 2.10 | 2.15 | 2.10 | 2.10 | 22,842 | |
| 02/28/2024 | 2.05 | 2.15 | 2.02 | 2.10 | 13,664 | |
| 02/27/2024 | 2.10 | 2.10 | 2.00 | 2.02 | 22,016 | |
| 02/26/2024 | 2.10 | 2.18 | 2.07 | 2.08 | 21,315 | |
| 02/23/2024 | 2.06 | 2.10 | 2.06 | 2.06 | 11,961 | |
| 02/22/2024 | 2.10 | 2.10 | 2.06 | 2.06 | 5,996 | |
| 02/21/2024 | 2.03 | 2.12 | 2.03 | 2.06 | 14,503 | |
| 02/20/2024 | 2.06 | 2.10 | 2.05 | 2.06 | 11,088 | |
| 02/16/2024 | 2.11 | 2.13 | 2.07 | 2.07 | 4,689 | |
| 02/15/2024 | 2.08 | 2.11 | 2.06 | 2.09 | 9,473 | |
| 02/14/2024 | 2.03 | 2.11 | 2.03 | 2.11 | 7,331 | |
| 02/13/2024 | 2.17 | 2.17 | 2.05 | 2.05 | 29,456 | |
| 02/12/2024 | 2.24 | 2.24 | 2.17 | 2.17 | 6,877 | |
| 02/09/2024 | 2.16 | 2.24 | 2.16 | 2.24 | 7,337 | |
| 02/08/2024 | 2.18 | 2.22 | 2.16 | 2.17 | 7,673 | |
| 02/07/2024 | 2.17 | 2.22 | 2.17 | 2.22 | 2,596 | |
| 02/06/2024 | 2.17 | 2.22 | 2.17 | 2.17 | 9,331 | |
| 02/05/2024 | 2.16 | 2.23 | 2.16 | 2.17 | 19,397 | |
| 02/02/2024 | 2.19 | 2.23 | 2.16 | 2.23 | 5,751 | |
| 02/01/2024 | 2.17 | 2.24 | 2.17 | 2.22 | 9,599 | |
| 01/31/2024 | 2.19 | 2.25 | 2.19 | 2.19 | 3,054 | |
| 01/30/2024 | 2.20 | 2.25 | 2.20 | 2.25 | 7,784 | |
| 01/29/2024 | 2.14 | 2.27 | 2.14 | 2.24 | 8,946 | |
| 01/26/2024 | 2.16 | 2.26 | 2.15 | 2.19 | 8,904 | |
| 01/25/2024 | 2.23 | 2.26 | 2.19 | 2.26 | 4,804 | |
| 01/24/2024 | 2.23 | 2.26 | 2.19 | 2.19 | 28,538 |
About PharmaCyte Biotech Stock history
PharmaCyte Biotech investors dedicate a lot of time and effort to gaining insight into how a market's past behavior relates to its future. Access to timely market data for PharmaCyte is vital when making an investment decision, and regardless of whether you use fundamental or technical analysis, your return on investment in PharmaCyte Biotech will depend on recognizing future opportunities and eliminating past mistakes. Historical data analysis is the study of market behavior over a given time. Recorded market-related data such as price, volatility, and volume can be quantified and studied over a defined period. Through a detailed examination of a market's past behavior, traders and investors can gain perspective on the inner workings of that market. The information obtained throughout analyzing PharmaCyte Biotech stock prices may prove useful in developing a viable investing in PharmaCyte Biotech
| Last Reported | Projected for Next Year | ||
| Common Stock Shares Outstanding | 22.4 M | 21.3 M | |
| Net Loss | -4.9 M | -5.1 M |
PharmaCyte Biotech Stock Technical Analysis
PharmaCyte Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
Did you try this?
Run Fundamentals Comparison Now
Fundamentals ComparisonCompare fundamentals across multiple equities to find investing opportunities |
| All Next | Launch Module |
PharmaCyte Biotech Technical and Predictive Indicators
Predictive indicators are helping investors to find signals for PharmaCyte Biotech's price direction in advance. Along with the technical and fundamental analysis of PharmaCyte Stock historical price patterns, it is also worthwhile for investors to track various predictive indicators of PharmaCyte to make sure they correctly time the market and exploit it's hidden potentials. Even though most predictive indicators are useful for the short-term horizon, it's virtually impossible to predict the unforeseen market. For traders with a short-term horizon, predictive indicators add value when properly applied. Long-term investors, however, may find many predictive indicators less useful.
| Risk Adjusted Performance | 0.0225 | |||
| Jensen Alpha | (0.02) | |||
| Total Risk Alpha | (0.22) | |||
| Treynor Ratio | 0.0463 |
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in PharmaCyte Biotech. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade PharmaCyte Stock refer to our How to Trade PharmaCyte Stock guide.Note that the PharmaCyte Biotech information on this page should be used as a complementary analysis to other PharmaCyte Biotech's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Complementary Tools for PharmaCyte Stock analysis
When running PharmaCyte Biotech's price analysis, check to measure PharmaCyte Biotech's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy PharmaCyte Biotech is operating at the current time. Most of PharmaCyte Biotech's value examination focuses on studying past and present price action to predict the probability of PharmaCyte Biotech's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move PharmaCyte Biotech's price. Additionally, you may evaluate how the addition of PharmaCyte Biotech to your portfolios can decrease your overall portfolio volatility.
| Content Syndication Quickly integrate customizable finance content to your own investment portal | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Portfolio Holdings Check your current holdings and cash postion to detemine if your portfolio needs rebalancing | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is PharmaCyte Biotech's industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of PharmaCyte Biotech. If investors know PharmaCyte will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about PharmaCyte Biotech listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.48) | Return On Assets (0.05) | Return On Equity (0.02) |
The market value of PharmaCyte Biotech is measured differently than its book value, which is the value of PharmaCyte that is recorded on the company's balance sheet. Investors also form their own opinion of PharmaCyte Biotech's value that differs from its market value or its book value, called intrinsic value, which is PharmaCyte Biotech's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because PharmaCyte Biotech's market value can be influenced by many factors that don't directly affect PharmaCyte Biotech's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between PharmaCyte Biotech's value and its price as these two are different measures arrived at by different means. Investors typically determine if PharmaCyte Biotech is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, PharmaCyte Biotech's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.